Triptoréline : L'option nucléaire PCT en une seule injection pour un redémarrage complet de l'axe HPTA
Novo Pharma Research Team
Recherche Novo Pharma · synthèse de littérature révisée par les pairs
Triptoréline : L'option nucléaire PCT en une seule injection pour un redémarrage complet de l'axe HPTA
Meta Description : La PCT à la triptoréline utilise une dose unique de 50-100mcg d'agoniste GnRH pour déclencher un redémarrage complet de l'axe HPTA après un arrêt sévère par les SAA. Découvrez le protocole, les risques et quand c'est justifié.
Références :
- Engel JB, Schally AV. Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007;3(2):157-167.
- Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994;45:391-405.
- Belchetz PE, et al. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631-633.
- Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet. 2001;358(9295):1793-1803.
- Depenbusch M, et al. Maintenance of spermatogenesis after complete hypogonadotropic suppression by GnRH-agonist: case report. Hum Reprod. 2002;17(6):1556-1560.
- Heber D, Swerdloff RS. Gonadotropin-releasing hormone analog and testosterone synergistically inhibit spermatogenesis. Endocrinology. 1981;108(6):2019-2021.
- McLeod DG. Hormonal therapy: historical perspective to future directions. Urology. 2003;61(2 Suppl 1):3-7.
- Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev. 1986;7(1):44-66.
- Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
- Ramasamy R, et al. Return of spermatogenesis after testosterone replacement therapy or anabolic-androgenic steroid use. Asian J Androl. 2015;17(3):375-380.
All compounds discussed and sold through Novo Pharma are intended strictly for laboratory and in-vitro research purposes. Products are not for human or animal consumption, not for use in food, cosmetics, or medicinal applications, and not for any therapeutic or diagnostic use.
The information on this page is provided for educational context and documents findings from published research. It is not medical advice, not a recommendation, and not a suggestion that any compound be used outside of a controlled research environment. Consult a qualified healthcare professional for any medical or health-related decision.
By purchasing, you confirm you are a qualified researcher, accept full responsibility for proper handling and disposal, and agree to use compounds in compliance with all applicable local, provincial, and federal laws.